PD1 Clinical Trials

1 recruiting

PD1 Trials at a Glance

7 actively recruiting trials for pd1 are listed on ClinicalTrialsFinder across 5 cities in 3 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Beijing, Beijing, and Bethesda. Lead sponsors running pd1 studies include Sun Yat-sen University, National Human Genome Research Institute (NHGRI), and Peking University Cancer Hospital & Institute.

Browse pd1 trials by phase

Treatments under study

About PD1 Clinical Trials

Looking for clinical trials for PD1? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

ExanthemaLichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
University of Zurich20 enrolled1 locationNCT06399029
Recruiting

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

Metabolic DiseaseAMPD3, OMIM*102772, AMP Deaminase DeficiencyAK1, OMIM *103000, Adenylate Kinase Deficiency+25 more
National Human Genome Research Institute (NHGRI)999 enrolled1 locationNCT06092346
Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular CarcinomaBevacizumabAnti-PD1/PDL1 Antibody
Sun Yat-sen University240 enrolled1 locationNCT06323382
Recruiting
Not Applicable

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Hepatocellular CarcinomaLenvatinibTranscatheter Arterial Chemoembolization+1 more
Sun Yat-sen University32 enrolled1 locationNCT06740370
Recruiting
Not Applicable

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University60 enrolled1 locationNCT06550921
Recruiting

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
Phase 1

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Breast CancerLiver CancerLung Cancer+5 more
Second Affiliated Hospital of Guangzhou Medical University40 enrolled1 locationNCT04842812